Deborah Charych
Directeur/Membre du Conseil chez SKYE BIOSCIENCE, INC.
Fortune : - $ au 30/04/2024
Profil
Deborah Charych was the founder of Third Rock Ventures LP (2017) and Rayzebio, Inc. (2018) where she held the title of Chief Technology Officer.
She is also the founder of Maze Therapeutics, Inc. Deborah's current job is as an Independent Director at Skye Bioscience, Inc. where she started in 2023.
Her former jobs include Director-Preclinical & Translational Research at Nektar Therapeutics (2010-2018) and Director-Biologics Process Development at Five Prime Therapeutics, Inc. (2007-2010).
Deborah received her undergraduate degree from Carnegie Mellon University and her doctorate from the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SKYE BIOSCIENCE, INC.
-.--% | 29/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Deborah Charych
| Sociétés | Poste | Début |
|---|---|---|
| SKYE BIOSCIENCE, INC. | Directeur/Membre du Conseil | 14/02/2023 |
Anciens postes connus de Deborah Charych
| Sociétés | Poste | Fin |
|---|---|---|
Third Rock Ventures LP
 Third Rock Ventures LP Investment ManagersFinance Third Rock Ventures LP seeks investment opportunities in life science companies located in the United States. The fund targets companies operating in the fields of sciences primarily in biotechnology, biopharmaceutical and medical devices. It provides financing for early stage capital requirements with an initial investment size of up to $30 million. It also acts as a lead investor. | Fondateur | 01/01/2019 |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | 01/01/2018 |
| FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2010 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Fondateur | - |
| RAYZEBIO, INC. | Fondateur | - |
Formation de Deborah Charych
| Carnegie Mellon University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| RAYZEBIO, INC. | Health Technology |
| SKYE BIOSCIENCE, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| Entreprise privées | 3 |
|---|---|
Third Rock Ventures LP
Third Rock Ventures LP Investment ManagersFinance Third Rock Ventures LP seeks investment opportunities in life science companies located in the United States. The fund targets companies operating in the fields of sciences primarily in biotechnology, biopharmaceutical and medical devices. It provides financing for early stage capital requirements with an initial investment size of up to $30 million. It also acts as a lead investor. | Finance |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |